Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Keith, S. J. Articles by Lachaux, B. Search for Related Content PubMed Citation Articles by Keith, S. J. Articles by Lachaux, B. Treatment Compliance Schizophrenia Spectrum Disorders Atypical Neuroleptics Related Article

Practical Application of Pharmacotherapy With Long-Acting Risperidone for Patients With Schizophrenia

OBJECTIVE: It is now generally accepted that the use of second-generation, or atypical, antipsychotics for schizophrenia represents an advance over conventional antipsychotic agents. However, adherence continues to be a problem, as with other medications for chronic disorders. Long-acting formulations of conventional antipsychotics partly address adherence problems, but their use is limited by tolerability issues. This article provides practical advice to physicians on the characteristics of patients who would benefit from treatment with long-acting atypical antipsychotic agents and offers suggestions on how to initiate treatment. METHODS: A literature search for studies published between 1980 and 2003 that evaluated the treatment of patients with schizophrenia with long-acting atypical agents was conducted by using MEDLINE and EMBASE. The primary search parameters were "schizophrenia," "atypical," "antipsychotic," and "long-acting." As expected, long-acting risperidone was the only long-acting atypical agent identified; thus this article focuses on practical advice and suggestions on how to initiate therapy with long-acting risperidone. RESULTS AND DISCUSSION: From the results of the literature search and the discussion of a panel of experts at a meeting held in Dublin in 2003 and supported by Johnson & Johnson, it is possible to conclude that long-acting risperidone has demonstrated efficacy and tolerability, even among patients who are considered clinically stable on other antipsychotics. Most patients can switch safely and effectively to long-acting risperidone if appropriate strategies are applied. Long-acting risperidone provides a new and promising therapeutic option for the treatment of schizophrenia.

Related Article:

Impractical Features of Long-Acting Risperidone

Mark A. Amdur
Psychiatr Serv 2004 55: 1443. [Full Text] [PDF]

This article has been cited by other articles:

				M. Olfson, S. C. Marcus, and H. Ascher-Svanum Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone Schizophr Bull, November 1, 2007; 33(6): 1379 - 1387. [Abstract] [Full Text] [PDF]

				A. Mohl, K. Westlye, S. Opjordsmoen, A. Lex, A. Schreiner, M. Benoit, P. Braunig, and R. Medori Long-acting risperidone in stable patients with schizoaffective disorder J Psychopharmacol, September 1, 2005; 19(5_suppl): 22 - 31. [Abstract] [PDF]

				N. R. Pinninti and R. Mago Use of Long-Acting Risperidone Psychiatr Serv, January 1, 2005; 56(1): 105 - 105. [Full Text] [PDF]

				M. A. Amdur Impractical Features of Long-Acting Risperidone Psychiatr Serv, December 1, 2004; 55(12): 1443 - 1443. [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us